Tumor suppressor RKIP inhibits prostate cancer cells metastasis and sensitizes prostate cancer cells to docetaxel treatment

Rok, strany: 2018, 228 - 233

Raf Kinase inhibitory protein (RKIP) is a well-established metastasis suppressor that is frequently down-regulated in aggressive cancers. However, the impact of RKIP on cancer cell invasion and metastasis in prostate cancer is still elusive. To this end, we overexpressed RKIP in two prostate cancer cell lines. We found that overexpression of RKIP inhibited prostate cancer cells proliferation, migration and invasion. Mechanistically, we found that RKIP overexpression led to the down-regulation of NF-kB signaling pathway and the inhibition of epithelial-to-mesenchymal transition, which is the important step for cancer metastasis. In addition, overexpression of RKIP can promote the drug effects of docetaxel on prostate cancer cell lines. In conclusion, overexpression of RKIP significantly inhibits prostate cancer cell migration and metastasis, and overexpression of RKIP could aid prostate cancer treatment and therapy.

ISO 690:

Zhu, C., Li, W., Guo, Y., Chen, L., Li, G., Yu, J., Shu, B., Peng, S. 2018. Tumor suppressor RKIP inhibits prostate cancer cells metastasis and sensitizes prostate cancer cells to docetaxel treatment. In NEOPLASMA, vol. 65, no.2, pp. 228-233. 0028-2685.

APA:

Zhu, C., Li, W., Guo, Y., Chen, L., Li, G., Yu, J., Shu, B., Peng, S. (2018). Tumor suppressor RKIP inhibits prostate cancer cells metastasis and sensitizes prostate cancer cells to docetaxel treatment. NEOPLASMA, 65(2), 228-233. 0028-2685.